According to SPER Market Research, the cell-based assays market is estimated to reach USD 30.4 billion by 2030 with a CAGR of 7.4%.
Rising prevalence of infectious diseases has increased the research activities for development of novel therapeutics. High adoption of cell-based assays in drug development process is driving the growth of this market.
Cell-based assays are the tools in life science research based on cell culture methods. In such assays, live cells are grown in vitro to be used as model systems to evaluate physiology and biochemistry of healthy & diseased cells. The quantitative amount, functional activity and presence is provided by these assays.
Cell-based assays offer many advantages as compared to biochemical assays carried out in vitro. Cell-based assays are tissue-specific response generating, consistent in analysis and highly efficient. Many pharmaceutical and biotechnology companies are moving towards cell-based assays in place of biochemical assays to improve the lead identification and optimization during the drug discovery process.
The consumables market is the largest product segment by share in this market. The large share of this segment is mainly ascribed by repeat purchases of consumables and increasing preliminary studies for drug development. North America dominated the market by regional segmentation owing to rising funding from government and private organizations, increasing penetration of CROs, regulatory assistance for drug development and high adoption of latest technology in this region.
The global cell-based assays market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as AAT Bioquest, Becton, Dickinson and Company, BioAgilytix Labs, Charles River Laboratories, Danaher Corporation, Lonza, Merck KGaA, PerkinElmer, Inc., Promega Corporation, Reaction Biology Corporation, Thermo Fisher Scientific.
SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for product & service segment- Consumables (Reagents, Assay Kits [Reporter Gene Assays, Cell Growth Assays, Second Messenger Assays, Cell Death Assays, Other Assay Kits], Cell Lines [Immortalized Cell Lines, Primary Cell Lines, Stem Cell Lines]), Microplates, Probes & Labels, Other Consumables, Instruments & Software, Services; for type segment- Drug Discovery (Toxicity Studies, Pharmacodynamic Studies, Pharmacokinetic Studies), Basic Research, Other Application; for end user segment- Pharmaceutical & Biopharmaceutical Companies, CROs, Research & Academic Institutes. This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World.
This study also encompasses various drivers and restraining factors for this market for the forecast period. Various growth opportunities are also discussed in the report.